Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa

AIDS

Volumn 24, Issue 12, 2010, Pages 1849-1855

  Komati, Stephanus ^a   Shaw, Pamela A ^b   Stubbs, Nomso ^a   Mathibedi, Monkwe J ^a   Malan, Lizette ^a   Sangweni, Phumelele ^a   Metcalf, Julia A ^b   Masur, Henry ^b   Hassim, Shaheen ^a  

^a South African National Defence Force   (South Africa)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Death; HIV AIDS; Outcome; South Africa; Tuberculosis

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; RIFABUTIN; RIFAMPICIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS; VIREMIA; VIRUS LOAD; VIRUS SURVIVAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; VIRAL LOAD; VIREMIA;

EID: 77954725917     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833a2507     Document Type: Article

References (18)

1. Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, et al. Infections with Mycobacterium tuberculosis and Myco-bacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med 2000; 162:865-872.
2. Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort study. JAMA 1999; 282:2220-2226.
3. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-asso-ciated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000; 4:1026-1031.
4. Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, Matteelli A, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14:1985-1991.
5. Badri M, Wilson D, Wood R. Effect of highly active antiretro-viral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-2064.
6. Ralph AP, Anstey NM, Kelly PM. Tuberculosis into the 2010s: is the glass half full? Clin Infect Dis 2009; 49:574-583.
7. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4:325-333.
8. World Health Organization. Global tuberculosis control. Epidemiology, strategy, financing. World Health Organization Conference. Geneva: World health Organization; 2009.
9. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172:123-127; Epub 2005 Apr 2001.
10. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-2116.
11. Santoro-Lopes G, de Pinho AM, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-546; Epub 2002 Jan 2007.
12. Girardi E, Antonucci G, Vanacore P, Palmieri F, Matteelli A, Iemoli E, et al. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J 2004; 24:11-17.
13. 3 in South Africa. 17th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal, Canada; 2009.
14. National Department of Health South Africa. National Antire-troviral Treatment Guidelines; 2004. http://www.doh.gov.za/docs/factsheets/guidelines/ artguidelines04/index.html [Accessed 19 February 2010].
15. Whalen CC, Nsubuga P, Okwera A, Johnson JL, Hom DL, Michael NL, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14:1219-1228.
16. Zhou J, Elliott J, Li PC, Lim PL, Kiertiburanakul S, Kumarasamy N, et al. Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database. BMC Infect Dis 2009; 9:46.
17. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 2001; 5:225-232.
18. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207; quiz CE201-204.